Thanks to Daniel Gruffat, M.S. and the Nanome team for guiding us through molecular design of peptides against GPCRs in virtual reality today. Now we know what its like to "be" a peptide!

The Surfer Mentality When a surfer gets up on a wave, they enjoy the moment, even though they know the wave will eventually end (and the next one may crash on their head). They fully enjoy THIS wave—knowing that there are always more waves coming.

Our co-founder Mark Fingerhuth was interviewed for Toronto Life Magazine along with Aharon Brodutch of IonQ, Christian Weedbrook of Xanadu, and Michele Mosca of evolutionQ. Big thanks to Barry Jordan Chong for the amazing & lighthearted conversation!

Many unsolved problems exist in ML safety which are not solved by closed-source GPT models. As LLMs become more prevalent, it becomes increasingly important to build safe and reliable systems. Some key research areas: 🧵

Come and hang out at the ProteinQure HQ tomorrow evening for the next Bits in Bio meetup!

Over the weekend our team "Pep(tides) in your step" completed the #CNTowerClimb, raising donations and awareness for WWF-Canada. We'd like to thank actin, myosin, and all the other proteins abundant in muscle fibre for the hard work! 🦵🦵

An amazing announcement that's been in the works for quite some time! I'm so proud of our entire ProteinQure team that's been working hard on making this a reality 🧪🔬👩‍🔬👨‍🔬

Just added ProteinQure to this awesome list and I love reading about all the other for-profit startups working on a better future 🌍✨

Learn about ProteinQure's promising new breast cancer drug PQ-001 in this thread:

In this interview with the BOLD Community, I discuss how to cultivate a culture of innovation, #BOLD decisions made at @ProteinQure and why we like riding rollercoasters. boldcommunity.org/mind/mark-fing…

.ProteinQure just turned 6 years old! Can't thank my co-founders (Tomas Babej, Chris Ing & Lucas Siow) enough for all these amazing years 🙏

Breast cancer is a complex disease with unique subtypes. As part of #BreastCancerAwarenessMonth our latest blog post explores the science behind HER2, ER, and PR receptors. Together, we're making strides in the fight against breast cancer! tinyurl.com/pq-bcam

Exciting to see more attention drawn to SORT1. We're looking forward to sharing results from our sortilin-mediated drug delivery platform, with novel, high-affinity targeting ligands and the best siRNA delivery data to date

Meet us at JPM in San Francisco next week! #JPM24

Big milestone at ProteinQure regarding our targeted therapeutic against triple-negative breast cancer! I'm incredibly proud of our entire team and excited to keep working towards our first clinical trial.

We closed our $11 M Series A. This funding drives our AI-designed peptide therapeutic into the clinic and enables us to scale our platform for precision drug delivery against tough diseases. Dare to Deliver!